AlphaFold predicted structure
MYMK · A6NI61

Mean pLDDT
90.4/ 100
Very high
221 residues
Confidence breakdown
- Very high(≥ 90)78%
- Confident(70–90)10%
- Low(50–70)12%
- Very low(< 50)1%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
myomaker, myoblast fusion factor
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Arthrogryposis
BIALLELIC, autosomal or pseudoautosomalClefting
BIALLELIC, autosomal or pseudoautosomalCongenital myopathy
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalHydrocephalus
BIALLELIC, autosomal or pseudoautosomalCongenital muscular dystrophy
BIALLELIC, autosomal or pseudoautosomalCarey-Fineman-Ziter syndrome
Carey-Fineman-Ziter syndrome
hereditary disease
multinodular goiter
ovarian dysfunction
muscular dystrophy, limb-girdle, autosomal dominant 4
autosomal recessive spondylocostal dysostosis
myopathy, reducing body, X-linked, childhood-onset
spondyloepiphyseal dysplasia tarda, autosomal dominant
myopathy, centronuclear, 6, with fiber-type disproportion
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein myomaker
Myoblast-specific protein that mediates myoblast fusion, an essential step for the formation of multi-nucleated muscle fibers (PubMed:28681861). Actively participates in the membrane fusion reaction by mediating the mixing of cell membrane lipids (hemifusion) upstream of MYMX. Acts independently of MYMX (By similarity). Involved in skeletal muscle regeneration in response to injury by mediating the fusion of satellite cells, a population of muscle stem cells, with injured myofibers (By similarity). Also involved in skeletal muscle hypertrophy, probably by mediating the fusion of satellite cells with myofibers (By similarity)
MYMK · A6NI61

Mean pLDDT
90.4/ 100
Very high
221 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0